WV Health Right, Inc.
This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard care for HIV prevention and be offered enrollment in the digital health companion program. Goal of the study is to evaluate medication adherence and persistence in patients receiving CAB-LA vs oral PrEP and who engage with a digital health companion program.
The study will evaluate the extent to which real-world use of CAB-LA for PrEP in underserved populations impacts PrEP adherence, persistence, retention-in-care, and PROs compared with oral PrEP. Additionally, the study will examine the implementation of a digital health companion program that leverages education and behavioral economics to support patients on PrEP, and assess clinician perspectives as well as barriers to, and facilitators for implementation of CAB-LA in a patient-centered medical home. Primary Objective To evaluate medication adherence and persistence in patients receiving CA…
Inclusion Criteria: * Initiation of or current user of PrEP with CAB-LA, daily FTC/TDF, or daily FTC/TAF prescribed in accordance with the WVHR standard of care practices (based practices on CDC PrEP 2021 Clinical Practice Guidelines) by a licensed HCP * PrEP dispensed by WVHR pharmacy * Access to a smart phone Exclusion Criteria: * Receiving HIV PrEP care outside of WVHR * Positive HIV diagnosis * Contraindication to oral or injectable PrEP therapy * Receiving oral bridging therapy prior to injectable PrEP therapy
Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
Arctuva estimate
Verify or correct the compensation shown for this listing.